HALLE/SAALE, Germany, 20 November 2015 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is scheduled to attend and present at the following conferences:
23-24 November 2015, Antwerp, Belgium
Dr Konrad Glund, CEO, will be attending and hosting meetings
The EBDC is an annual event that connects leading decision makers from international pharmaceutical companies and European biotech firms together with representatives of private equity and venture capital companies. The conference is attended by CEOs, managing directors and senior business development managers. Topics of interest in 2015 will include generation medicines for autoimmune diseases, companion diagnostics and other key market drivers in oncology, alternatives for biotech financing or evaluation if the hype on immunotherapies can realize its promise.
23-25 November, Sheraton Airport Hotel and Conference Center, Frankfurt/Main, Germany
Dr Hendrik Liebers, CFO, to present on 23 November at 17:00 CET in Room Oslo
With thousands of participants from the financial community, entrepreneurs, investors and analysts, the event establishes an international network and information platform across Europe. As one of the world’s largest exchange organisations, Deutsche Börse AG and the KfW, a leading development bank, provide an optimal platform to promote greater engagement between capital seeking companies and investors.
(3) Degroof Petercam Healthcare Seminar
25 November 2015, Hotel Bloom, Brussels, Belgium
Dr Hendrik Liebers, CFO, will be attending and hosting meetings
The seminar enables delegates to attend one-to-one meetings with senior company management as well as meetings in small group.
(4) TN2 conference
3-4 December 2015, VU Medical Center, Amstelzaal & Foyer, ZH0A2De Boelelaan 111 1081 HV Amsterdam, the Netherlands
Dr Stephan Schilling to hold a lecture on 4 December at 11:00 CET on the topic: “Developing anti pGlu-Abeta therapies – a differentiated Abeta approach to treat Alzheimer’s disease”
Dr Stephan Schilling has worked for Probiodrug until 2013. Today, he is now the head of the Drug Biochemistry Unit at the Fraunhofer Institute for Cell Therapy and Immunology (IZI). As a member of the research team and Director of Enzymology at Probiodrug he is the inventor of several patents, first and co-author of key publications on the role of pGlu-Abeta and glutaminyl cyclases in Alzheimer’s disease.
The second edition of TN2, organised by the Transnational Neuroscience network, will provide an opportunity for both academia and industrial partners to explore new collaborations and insights. The conference will connect preclinical and clinical researchers of all academic levels, business developers, and representatives from small-, medium-, and large-sized companies.
The scientific topics will include preclinical research and disease mechanism, new biomarkers and therapy or Industry-Academia collaborations. The second day of the conference will be focused on dementia from basic science to care, including as diverse topics as novel biomarkers, molecular imaging and clinical aspects of dementia.
8-9 December 2015, The Charles Hotel – Sophienstraße 28 – 80333 Munich, Germany
Dr Hendrik Liebers, CFO, to present on 8 December at 16:50 CET
The Kapitalmarkt Konferenz is organised by GBC AG and attracts analysts, financial journalists, as well as asset and fund management companies. Since 2011, the conference offers selected companies to present as well as host one-to-one meetings.
For more information, please contact:
Dr Konrad Glund, CEO
Mary Clark, Supriya Mathur, Alexia Faure
Tel: +44 (0) 203 440 5657
Notes to Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease.
Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research. www.probiodrug.de
About Alzheimer’s disease
Alzheimer’s disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, 44 million people worldwide currently live with the condition and this number is expected to almost double by 2030 and to more than triple by 2050 to over 132 million. Alzheimer’s also has an estimated, global societal cost of over $600 billion (World Alzheimer Report 2014).
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.